Argent BioPharma (ASX:RGT) swaps CannEpil rights for US$5.5m in Mercer debt forgiveness

The deal kills a secured debt overhang, keeps the IP, and adds a 15% royalty

Argent BioPharma (ASX:RGT) has done something small-cap biotechs rarely pull off. It has turned a secured debt problem into a global licensing deal without giving away the underlying asset.

The company announced today that it has licensed global rights to CannEpil, its drug-resistant epilepsy therapy, to NYSE-listed Splash Beverage Group. The upfront consideration is US$5.5 million. But instead of arriving as cash, it lands as the forgiveness of US$5.5 million of convertible notes owed to Mercer Street Global Opportunity Fund. Mercer walks away with SBEV preferred equity, and Argent’s balance sheet loses its principal secured liability in one step.

Argent keeps 100% of the CannEpil intellectual property. It keeps the EU-GMP manufacturing role, priced at cost plus up to 20% margin. And it takes a 15% royalty on net revenues for the longer of 10 years from first sale in each country or the last patent expiry.

For a company that spent the past year absorbing the AusCann acquisition and building out its neuro-immune pipeline, removing a senior secured creditor without issuing a single new share to shareholders is a rare piece of financial engineering.

Why the Mercer debt matters more than the licence headline

Convertible notes held by a specialist fund like Mercer are the kind of liability that quietly shapes every strategic decision a small biotech makes. They sit senior, they carry security interests, and they usually convert into equity at prices that punish existing holders.

Removing that overhang changes the maths on future capital raises, on the mooted US listing, and on the company’s ability to talk to Tier 1 partners without a secured creditor sitting at the table. That is the real prize here, not the licence itself.

The skeptical read is that Argent has effectively sold a decade of upside on its most advanced neurological asset to escape a financing structure it should not have taken on in the first place. We think that is fair criticism, but the cleanup was necessary before the next chapter could start.

What Argent actually keeps in the deal

The 15% net revenue royalty is at the higher end of what biotechs of this size typically negotiate. The perpetual manufacturing right through Argent’s EU-GMP facilities adds a second revenue stream that scales with SBEV’s commercial success.

SBEV also carries the development risk from here. It must initiate a Phase I within 24 months, a Phase II within 48 months, and file an NDA with the FDA on successful trials. Argent’s clinical spend on CannEpil effectively stops, which frees capital for CimetrA and the broader neuro-immune portfolio.

CannEpil already has commercial traction. Full reimbursement in Ireland, active sales into the UK, Germany and Australia, and the largest shipment in the product’s history at 1,000 units into Ireland. Royalties start flowing from an actual revenue base, not a hypothetical one.

The SBEV question the market will ask

Splash Beverage Group is mid-transformation from a drinks business to what it calls a cannabinoid health and wellness platform. That will raise eyebrows. A neurology asset with an active FDA IND programme is not an obvious fit for a company whose historical revenue came from bottled beverages.

SBEV’s ability to fund a Phase I, Phase II and NDA pathway is the variable investors need to underwrite. Argent has protected itself with termination rights tied to milestone failures and a five-year deadline on US regulatory approval, but a stalled partner still costs Argent time even when it does not cost equity.

Can the balance sheet reset unlock the US listing this year?

The transaction lines up neatly with the US national exchange listing that management has been signalling since the AusCann deal closed. A clean balance sheet, a live royalty stream, an EU-GMP manufacturing base, and a US-listed partner carrying the clinical spend is a materially easier story to take to American institutional investors than what Argent was carrying yesterday.

What we would want to see over the next 12 months is confirmation that SBEV has the capital to hit the Phase I milestone, meaningful progress on the CimetrA programme now that CannEpil development spend has been transferred, and clarity on the US listing timeline. Investors can read our previous coverage of Argent’s transformation, including the AusCann acquisition, at stocksdownunder.

The debt is gone. The IP stays. The royalty starts on an already-selling product. From here, execution is the only thing that matters.